The countdown for the coronavirus vaccine and for ages 12-15 years began. The European Medicines Agency (EMA) announced on Monday, 3 May, that he started evaluating use at ages 12-15 years of the Pfizer vaccine / BioNTech v. Covid-19, following licensing applications for this age group in the European Union and the USA.
"Coreper will communicate the results of its evaluation, expected in June, unless additional information is deemed necessary ", said the Agency, based in Amsterdam, in a press release.
The EMA states that the Committee for Medicinal Products for Human Use "will conduct a rapid review of the data provided by the company marketing Comirnaty”, the trade name of the vaccine against Covid 19, developed by the German laboratory BioNTech and the American partner of Pfizer.
These data include the results of an ongoing clinical trial, with the participation of adolescents from their age 12 years, according to the EMA.
The BioNTech and Pfizer announced on Friday that they had asked the European Medicines Agency to extend to 12-15 years of licensing their vaccine in the European Union, which is currently limited to the above 16 years.
In the USA, the two companies filed in early April a similar license extension request issued by the Federal Drug Administration (FDA).
There is currently no vaccine for children, who are less exposed to the disease and for whom vaccination has not been a priority until now. Nevertheless, represent a significant part of the population and must also have been immunized in order to put a brake on the transmission of the disease, experts claim.